Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Anxiety Disorders Therapeutics Market is Forecast to Show Steady Growth until 2017
GlobalData estimates that the global anxiety disorders therapeutics market was valued at $3,698m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.3% over the next seven years, to reach $5,689m by 2017. This steady growth is primarily attributed to only one product launch for generalized anxiety disorder, disease awareness and alternate treatment options other than pharmacotherapy.
Current Treatment Options are Moderately Successful in Meeting Market Demand
GlobalData’s research indicates that the current market is well served by FDA (Food and Drug Administration)-approved drugs, off label drugs and alternative therapies such as cognitive behavioral therapy. Patients with the symptoms of anxiety disorders tend to depend more on alternative therapies such as cognitive behavioral therapy instead of medication. The current treatment options have moderate safety and efficacy. This indicates that the anxiety disorders therapeutics market has treatment options which are currently satisfying patients but that the treatment rates and awareness of anxiety disorders is low.
Strong Pipeline Candidates are Expected to Intensify Future Competition
GlobalData found that there are 54 products in the different stages of development. Lu AA21004, currently in Phase III, is the most promising products in the late stage pipeline. Drugs in the pipeline have shown encouraging response rates in pretreated patients and have great potential in the anxiety disorders therapeutics market. The pipeline candidates are mainly concentrated in Phase II of clinical development. These products are expected to meet some of the unmet needs of the market. They may also lead to an intensely competitive market. In summary, the global anxiety disorders therapeutics market is heading towards a highly competitive landscape.
Current Treatment Options Leave Moderate level of Unmet Need
The anxiety disorders therapeutics market has moderate unmet needs. This is due to lack of awareness among physicians and patients, and low diagnosis and treatment rates. The anxiety disorders therapeutics market has many FDA-approved therapies available for treatment. The therapies which are available for the treatment of anxiety have shown moderate efficacy and safety profiles, which lead to moderate unmet need. The market is wide open for novel entrants to fulfill the unmet need of the anxiety disorders therapeutics market.
GlobalData, the industry analysis specialist, has released its new report, “Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global anxiety disorders market. The report identifies the key trends shaping and driving the global anxiety disorders market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anxiety disorders sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
To purchase the report or for further information go to:
GlobalData is an industry analysis specialist company providing business information products and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.
Have Your Say
Rate this feature and give us your feedback in the comments section below